Patents by Inventor Sang Dal Rhee

Sang Dal Rhee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230018246
    Abstract: Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.
    Type: Application
    Filed: August 3, 2022
    Publication date: January 19, 2023
    Applicants: Research & Business Foundation Sungkyunkwan University, Korea Research Institute of Chemical Technology
    Inventors: Kwangho LEE, Sang Dal Rhee, Gildon Choi, Imran Ali, Chong Hak Chae, Moon Kook Jeon, Seok Hee Park, Youn Sook Lee
  • Publication number: 20220235011
    Abstract: Provided is a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof; a pharmaceutical composition for the prevention or treatment of Sirt6-associated diseases, including as an active ingredient, a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof; and a method for treating Sirt6-associated diseases including administering a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof to a subject in need.
    Type: Application
    Filed: May 29, 2020
    Publication date: July 28, 2022
    Applicants: ST PHARM CO., LTD., KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kyungjin KIM, Kwangrok KIM, Uk-Il KIM, Hyung Tae BANG, Seul Ki LEE, Kwan-Young JEONG, Seung Kyu KANG, Heejung JUNG, Sang Dal RHEE, Won Hoon JUNG, Jun Mi LEE
  • Patent number: 11365215
    Abstract: Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: June 21, 2022
    Assignees: Korea Research Institute of Chemical Technology, Research & Business Foundation Sungkyunkwan University
    Inventors: Kwangho Lee, Sang Dal Rhee, Gildon Choi, Imran Ali, Chong Hak Chae, Moon Kook Jeon, Seok Hee Park, Youn Sook Lee
  • Patent number: 10760056
    Abstract: Provided herein is a three-dimensional co-culture of adipocytes and macrophages, wherein, in a hydrogel scaffold containing adipocytes and macrophages, the adipocytes and the macrophages are co-cultured to form a fat-like tissue, which can be then utilized in the studies and medicine development for treating metastatic diseases associated with adipose tissue.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: September 1, 2020
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Ki Young Kim, Sung Bum Park, Sang Dal Rhee, Hi Youn Kim, Won Hoon Jung
  • Publication number: 20180208625
    Abstract: Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.
    Type: Application
    Filed: March 14, 2018
    Publication date: July 26, 2018
    Inventors: Kwangho Lee, Sang Dal Rhee, Gildon Choi, Imran Ali, Chong Hak Chae, Moon Kook Jeon, Seok Hee Park, Youn Sook Lee
  • Publication number: 20180208898
    Abstract: Provided herein is a three-dimensional co-culture of adipocytes and macrophages, wherein, in a hydrogel scaffold containing adipocytes and macrophages, the adipocytes and the macrophages are co-cultured to form a fat-like tissue, which can be then utilized in the studies and medicine development for treating metastatic diseases associated with adipose tissue.
    Type: Application
    Filed: July 22, 2016
    Publication date: July 26, 2018
    Inventors: Ki Young Kim, Sung Bum Park, Sang Dal Rhee, Hi Youn Kim, Won Hoon Jung
  • Publication number: 20170008924
    Abstract: Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.
    Type: Application
    Filed: July 8, 2016
    Publication date: January 12, 2017
    Inventors: Kwangho Lee, Sang Dal Rhee, Gildon Choi, Imran Ali, Chong Hak Chae, Moon Kook Jeon, Seok Hee Park, Youn Sook Lee
  • Patent number: 9321728
    Abstract: The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: April 26, 2016
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, HANDOK PHARMACEUTICALS CO., LTD.
    Inventors: Jin Hee Ahn, H. S. Pagire, Sang Dal Rhee, Ki Young Kim, Won Hoon Jung, Myung-Ae Bae, Jin Sook Song, Kwang-Rok Kim, Hyun Jung Kwak
  • Patent number: 9073906
    Abstract: Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1), and is useful in the treatment of various diseases that are mediated by 11?-HSD1.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: July 7, 2015
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Ki Young Kim, Jin Hee Ahn, Seung Kyu Kang, Sang Dal Rhee, Myung Ae Bae, Sung Hoon Ahn, Hee Youn Kim, Won Hoon Jung, Nam Sook Kang
  • Patent number: 8722674
    Abstract: Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: May 13, 2014
    Assignee: Hanall Biopharma Co., Ltd.
    Inventors: Hyae Gyeong Cheon, Kwang-Rok Kim, Sang Dal Rhee, Won Hoon Jung, Jong-Cheol Lee, Sung Wuk Kim, Sung Soo Jun
  • Patent number: 8648111
    Abstract: The present invention provides an N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: February 11, 2014
    Assignees: Hanall Biopharma Co., Ltd., Korea Research Institute of Chemical Technology
    Inventors: Sung Wuk Kim, Sung Soo Jun, Hyae Gyeong Cheon, Kwang Rok Kim, Sang Dal Rhee, Won Hoon Jung, Jong Cheol Lee
  • Patent number: 8642647
    Abstract: The present invention provides an N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: February 4, 2014
    Assignees: Hanall Biopharma Co., Ltd., Korea Research Institute of Chemical Technology
    Inventors: Sung Wuk Kim, Sung Soo Jun, Hyae Gyeong Cheon, Kwang Rok Kim, Sang Dal Rhee, Won Hoon Jung, Jong Cheol Lee
  • Publication number: 20140024636
    Abstract: Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1), and is useful in the treatment of various diseases that are mediated by 11?-HSD1.
    Type: Application
    Filed: March 30, 2012
    Publication date: January 23, 2014
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Ki Young Kim, Jin Hee Ahn, Seung Kyu Kang, Sang Dal Rhee, Myung Ae Bae, Sung Hoon Ahn, Hee Youn Kim, Won Hoon Jung, Nam Sook Kang
  • Patent number: 8198307
    Abstract: The present invention is directed to a novel imidazole derivative having an aryl piperidine substituent of formula (I) and a method for preparation thereof, and a pharmaceutical composition containing said imidazole derivative as an active ingredient for preventing or treating a MCH (melanine-concentrating hormone)-related disease.
    Type: Grant
    Filed: May 13, 2008
    Date of Patent: June 12, 2012
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Jee Hee Suh, Kyu Yang Yi, Nack Jeong Kim, Sung Eun Yoo, Kwang-Seok Oh, Hyae Gyeong Cheon, Mija Ahn, Byung Ho Lee, Won Hoon Jung, Sang Dal Rhee
  • Publication number: 20110237587
    Abstract: Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.
    Type: Application
    Filed: August 28, 2008
    Publication date: September 29, 2011
    Applicants: HANALL PHARMACEUTICAL COMPANY, LTD, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Hyae Gyeong Cheon, Kwang-Rok Kim, Sang Dal Rhee, Won Hoon Jung, Jong-Cheol Lee, Sung Wuk Kim, Sung Soo Jun
  • Publication number: 20110207810
    Abstract: The present invention provides an N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.
    Type: Application
    Filed: October 13, 2009
    Publication date: August 25, 2011
    Applicants: HANALL BIOPHARMA CO., LTD., KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Sung Wuk Kim, Sung Soo Jun, Hyae Gyeong Cheon, Kwang Rok Kim, Sang Dal Rhee, Won Hoon Jung, Jong Cheol Lee
  • Publication number: 20110196015
    Abstract: The present invention provides an N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.
    Type: Application
    Filed: October 13, 2009
    Publication date: August 11, 2011
    Applicants: HANALL BIOPHARMA CO., LTD., KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Sung Wuk Kim, Sung Soo Jun, Hyae Gyeong Cheon, Kwang Rok Kim, Sang Dal Rhee, Won Hoon Jung, Jong Cheol Lee
  • Publication number: 20100333217
    Abstract: Provided is a method for screening a composition for preventing or treating an osteoporosis and a metabolic bone disease using a TALLYHO/JngJ mouse, and more particularly, to a method for screening a compound effective in preventing and treating a disease caused by abnormalities of a bone metabolism including an osteoporosis, through assessment of a bone regeneration activity, such as acceleration of osteoblast differentiation, inhibition of osteoclast differentiation, variation of cytokine in a serum, as well as a bone mineral density and a bone mineral content in a femur, using a TALLYHO/JngJ mouse instead of a ovariectomized animal generally used in estimating the efficacy of a new osteoporosis medicine in an animal. The screening method has a simple and stable experiment procedure, and can be used in developing an agent for treating an osteoporosis of men and improving the bone mineral content.
    Type: Application
    Filed: April 23, 2008
    Publication date: December 30, 2010
    Applicant: KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Myung Ae Bae, Hyae Gyeong Cheon, Sung Eun Yoo, Hee Youn Kim, Won Hoon Jung, Sang Dal Rhee, Doh Yeon Ahn
  • Patent number: 7745439
    Abstract: The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.
    Type: Grant
    Filed: April 12, 2005
    Date of Patent: June 29, 2010
    Assignees: Korea Research Institute of Chemical Technology, Jeil Pharm. Co., Ltd., Korea Research Institute of Bioscience and Biotechnology, CJ Corp.
    Inventors: Hyae Gyeong Cheon, Sung-Eun Yoo, Sung Soo Kim, Sung-Don Yang, Kwang-Rok Kim, Sang Dal Rhee, Jin Hee Ahn, Seung Kyu Kang, Won Hoon Jung, Sung Dae Park, Nam Gee Kim, Sun Mee Kim, Kil Woong Mo, Jae Mok Lee, Hye Jung Kang, Koun Ho Lee, Jong Hoon Kim, Jeong-Hyung Lee, Seung Jun Kim
  • Patent number: 7741323
    Abstract: An indene derivative for selectively modulating the activities of peroxisome proliferator activated receptors (PPARs) having the following formula (I): wherein, R1 is C1-6 alkyl, C1-6 alkenyl, or C3-6 cycloalkyl, each of which is unsubstituted or substituted with one or more phenyl groups; R2 is H, CN, CO2Ra, CH2CO2Ra, CONRbRc, or phenyl; R3 is C1-6 alkyl, C3-6 cycloalkyl, naphthyl, phenyl, being each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, CN, NH2, NO2, ORa, phenyloxy, C1-6 alkyl, and C3-6 cycloalkyl; and R4, R5, R6, and R7 are each independently H, OH, OSO2CH3, O(CH2)mRe, CH2Rf, OCOCH2ORg, OCH2CH2ORg, OCH2CH?CHRg, or pyridine-2-yloxy, or R5 and R6 together form OCH2O.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: June 22, 2010
    Assignees: Korea Research Institute of Chemical Technology, Jeil Pharm. Co., Ltd., Korea Research Institute of Bioscience and Biotechnology, CJ Corp.
    Inventors: Hyae Gyeong Cheon, Sung-Eun Yoo, Sung Soo Kim, Sung-Don Yang, Kwang-Rok Kim, Sang Dal Rhee, Jin Hee Ahn, Seung Kyu Kang, Won Hoon Jung, Sung Dae Park, Nam Gee Kim, Jang Hyuk Lee, Sun Chul Huh, Jae Mok Lee, Seog Beom Song, Soon Ji Kwon, Jong Hoon Kim, Jeong-Hyung Lee, Seung Jun Kim